Sign in
Taking people in United StatesNo phase

Studying lingering inflammation in relapsing remitting multiple sclerosis

Studies lasting inflammation after treatment in people with multiple sclerosis.

Key facts

Who runs it
Washington University School of Medicine
Where
St Louis, United StatesSee the site
Trial code
Registry title
Smoldering Inflammation in MS
Status
Recruiting
People taking part
25 people, planned
Started
19 Jun 2024
Expected to end
30 Jun 2027
Type of study
Observational
Treatments tested
  • Radiotracer [11C]-CS1P1
  • Radiotracer [11C]-DPA-713
  • anti-CD20 MS treatment
  • Radiotracer [12F]-FDG
Record updated
28 April 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with active relapsing remitting multiple sclerosis who have not yet had MS treatment and are about to start a high efficacy MS drug.

Age
18 years or older
Sex
Women and men can join.
Disease stage
Multiple sclerosis with active disease: at least 1 enhancing lesion in the past 6 months.
Earlier treatment
No earlier MS treatment, except treatments for relapses such as corticosteroids or plasmapheresis. A high efficacy MS drug (ocrelizumab, natalizumab or a similar one) must be planned.
Biomarker or test result
People with a low binding polymorphism for TSPO cannot join. Recent blood tests (CBC and BMP) must show no significant problems.

Main reasons for not taking part

  • Low binding polymorphism for TSPO
  • Pregnant or breast-feeding women
  • Cannot safely have PET, CT or MRI scans, or severe claustrophobia
  • eGFR less than 60
  • Cannot safely have a lumbar puncture, for example blood thinners or a clotting disorder

The registry criteria, word for word

Show all 18 criteriaShow less

Who can take part

  • Male or female, any race
  • Age ≥ 18 years
  • Capable of providing written informed consent for volunteering to undergo research procedures
  • Diagnosis of MS as established by the referring physician and confirmed by the Sponsor-Investigator. Only patients with active disease, defined as at least 1 enhancing lesion present in the preceding 6 months, will be enrolled
  • Treatment naïve except for relapse-related treatments such as corticosteroids or plasmapheresis,
  • Planned initiation, at the discretion of the referring physician, of a high efficacy DMT. High efficacy DMT will be defined to include ocrelizumab, natalizumab, or any MS treatment in the opinion of the Sponsor-Investigator to have similar efficacy as the named treatments
  • Clinical labs, including at least a CBC and BMP, without significant abnormality as determined by the Sponsor-Investigator or designee, within the 3 months prior to enrollment

Who cannot take part

  • Currently undergoing radiation therapy
  • Current or recent (within 12 months prior to screening) participation in research studies involving radioactive agents such that the total research-related radiation dose to the participant in any given year would exceed 5 rem
  • Hypersensitivity to [11C]-CS1P1, [11C]-DPA-713, [18F]-FDG, or any of their excipients
  • Insulin dependent diabetes
  • Contraindication to lumbar puncture (LP), including use of antiplatelet therapy (other than aspirin 81mg), therapeutic anticoagulation, or space occupying intracranial mass. History of a coagulopathy is also exclusionary
  • Any condition that, in the opinion of the Sponsor-Investigator or designee could increase risk to the participant, limit the participant's ability to tolerate the research procedures or interfere with collection of the data (e.g., renal or liver failure, advanced cancer)
  • eGFR less than 60 (for gadolinium)
  • Presence of a low binding polymorphism for TSPO
  • Contraindications to PET, CT or MRI (e.g. certain incompatible electronic medical devices, inability to lie still for extended periods) that make it potentially unsafe for the individual to participate
  • Severe claustrophobia
  • Women who are currently pregnant or breast-feeding

Where in United States

  • Barnes Jewish Center for Clinical Imaging ResearchSt Louis, United StatesContact: Matthew R Brier, MD, PhDTaking people

About the trial

What the trial wants to find out

The goal of this observational study is to learn about inflammation in those with relapsing remitting Multiple Sclerosis (MS). The main questions it aims to answer are:

Read full original descriptionShow less

* How does abnormal neural inflammation compare to cellular and molecular inflammation in MS? * Once treated, why does abnormal inflammation persist?

The group in the trial

  • Participants

    Adults with MS taking part in this study.

    Treatment: Radiotracer [11C]-CS1P1, Radiotracer [11C]-DPA-713, anti-CD20 MS treatment, and Radiotracer [12F]-FDG

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Saves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Investigation of Smoldering Inflammation in Multiple Sclerosis
Plain-language title
Studying lingering inflammation in relapsing remitting multiple sclerosisGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 12 November 2026.
Record updated
28 April 2026